$HHSE.=.EXPONENTIAL-GROWTH--$50M+ in 2025, OTCQB.&.NASDAQ

New Post Public Reply Private Reply Replies (0) Message Board
HHSErocks Grumpy2 #2792
134
$HHSE.=.EXPONENTIAL-GROWTH--$50M+ in 2025, OTCQB.&.NASDAQ ARE NEXT.

Hannover House (HHSE) Positioned for Huge Growth from New Products and Financing


Press Release | 01/10/2025

https://www.otcmarkets.com/stock/HHSE/news/Ha...?id=464170

New York, New York--(Newsfile Corp. - January 10, 2025) - Independent media company Hannover House (OTC: HHSE), is launching into the new year with a roar, fueled by high-profile new properties and major financing. The 31-year old publishing house and entertainment distributor is forecasting revenue activities that should collectively exceed $50 million this year, said CEO Eric Parkinson. Peak annualized revenues for the company hit $20-million in 2007, when the company had a dozen feature film titles in the DVD budget bins at Walmart and Target stores. But the slow decline of the DVD sell-through market in favor of in-home streaming, brought a significant drop in revenues for Hannover during the past 10 years - as the company worked to reinvent its business model to pursue more lucrative activities.

TRUMP BOOK Cover - a powerful new book that reveals secret strategies for campaign success.

"The success we are delivering now is the result of a tremendous amount of hard work and detailed, in-depth business analysis," said Parkinson. "Many independent entertainment companies did not survive the transition from physical DVDs and Blu-ray Discs in favor of the consumer preference for in-home streaming. We have since developed two product categories and two distribution strategies that address these current market trends for consumer preferences," he continued.

UNHOLY SONG Teaser Art - acclaimed new thriller from HHSE has already spawned a sequel production.

First up for HHSE this year is a highly touted new book from best-selling author, Barr McClellan. "AMERICAN MANIFESTO: The Unstoppable Journey of President Donald J. Trump" will hit bookstores in late February, following a major promotional partnership with both Truth Social and the "X" social media platform. The book goes behind-the-scenes of the Trump campaign in 2024, to reveal strategies that successfully attracted voters from demographic groups that were long presumed to be democratic strongholds. As such, the book has great historic value as well as providing enlightening insights for both Republicans and Democrats on effective campaign strategies.

Also, in late February, the company is releasing the acclaimed horror-thriller, UNHOLY SONG to approximately 350 theaters in the United States. The company is concentrating on booking the film into the top performing locations for other independent, horror titles, such as the recently released hit, "TERRIFIER 3, " which has already grossed over $90 million in worldwide revenues . HHSE feels that Unholy Song is on track to gross over $10 million for the company, as well as to spark a new franchise series. Hannover House has already green-lit production for UNHOLY SONG 2 , to be shot in northern California in July. Discussions are already underway for a third installment in the series as well.

Also releasing this spring to theaters is the long awaited family feature, WILDFIRE: The Legend of the Cherokee Ghost Horse, " starring Anne Heche, Mo Brings Plenty ("Yellowstone" and Adrian Paul ("Highlander" . The film premiered last November at the Lone Star Film Festival in Fort Smith - but was delayed from release in order to complete some new music tracks, picture tweaks, and a 7.1 surround mix. HHSE is targeting approximately 300 theatres for the April 18 theatrical release, before a high profile streaming debut. Hannover House is forecasting revenues of $5.5 million from this title.

On a higher profile front, the company has closed financing arrangements for two major feature productions that collectively will cost over $35 million to produce . These features will be announced in detail separately, but will have a significant and positive impact to the company balance sheet, as well as providing high profile locomotive titles for the company's distribution activities. Both of these features have major level stars attached.

Regarding the company's stock, HHSE has taken steps to improve access for investors interested in purchasing its stock shares. This has been done through a recently enacted policy change with E*TRADE financial, as well as the company's forthcoming application to up-list the stock to the OTC: QB markets trading platform. At present, the company stock is traded on the OTC pink sheets, which Parkinson feels has less credibility with major investors and stock traders than some of the higher profile exchanges.

TEMPUS PORTA Teaser art - a major featured production in 2025 from Hannover House.

Last, but not least, the company has spent several years in development for a video-on-demand streaming service called MyFlix. With over 40 supplier Studios representing more than 15,000 feature titles, the MyFlix service will provide a free-to-view platform for consumers (like TUBI) but with a greater concentration on independent features than any other streaming service. The capital required to launch MyFlix has been a challenge for Hannover House, until now. With significant pre-sales for many of the company's new product releases, Hannover House feels it can allocate a percentage of these spring and summer 2025 revenues to bankroll the launch of this exciting new streaming service.

"This is a very exciting time for the company," said Parkinson. "We survived, we adapted, and now we are reaping the benefits of a successful business strategy. We are grateful to our shareholders and financing partners who helped us navigate through a changing media environment and to help launch this exciting new business plan," he concluded.

For more information, contact:

ERIC PARKINSON, 818-481-5277, EnterLinkMedia@gmail.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading